Premium
Future topical medications in chronic rhinosinusitis
Author(s) -
Miyake Michelle Me,
Bleier Benjamin S.
Publication year - 2019
Publication title -
international forum of allergy and rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.503
H-Index - 46
eISSN - 2042-6984
pISSN - 2042-6976
DOI - 10.1002/alr.22341
Subject(s) - medicine , chronic rhinosinusitis , intensive care medicine , disease , medline , antibiotics , dermatology , pathology , surgery , political science , law , microbiology and biotechnology , biology
Background Research has progressed rapidly in recent decades to better understand the etiopathogenesis and management paradigms of chronic rhinosinusitis (CRS). Although oral antibiotics often mitigate symptoms in acute CRS exacerbations, eradication of polymicrobial biofilms and multidrug‐resistant bacteria remains a challenge. The goal of this review is to summarize and discuss the potential and pitfalls of topical medications in the treatment of CRS. Methods A related literature review was performed using PubMed and Scopus, with only the English database included. Results The main therapies were selected and separated in sections. Details regarding future topical treatments of CRS were summarized and discussed. Conclusion The ease of access of the sinonasal mucosa positions CRS as a disease with high potential for local topical treatment. The ultimate adoption of topical agents will require continued expansion of our understanding of novel local targets in CRS as well as improved methods to deliver and retain the drug of interest at the site of activity.